Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super‐Response and Remission With Mepolizumab.

This article discusses a study that examined the effectiveness of the drug mepolizumab in treating severe eosinophilic asthma (SEA). The study used cluster analysis to identify two subgroups of patients with SEA, with Cluster 2 (C2) showing higher rates of response to the medication compared to Cluster 1 (C1). The study also found that family history of asthma was a predictor of treatment response. The research suggests that personalized treatment strategies based on subgroup identification could be beneficial for patients with SEA. Further validation studies are needed to confirm these findings. [Extracted from the article]